Antiatherogenic properties of metformin: the experimental evidence

Cardiovascular disease (CVD) is the major determining factor of morbidity and mortality in type 2 diabetic patients. The established relationship between type 2 diabetes and atherosclerosis has fuelled suggestions that anti-diabetic drugs with beneficial effects on CV risk factors may help attenuate...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes & metabolism 2003-09, Vol.29 (4), p.6S71-6S76
Main Authors: Mamputu, J.C., Wiernsperger, N.F., Renier, G.
Format: Article
Language:English
Subjects:
Animals
Aortic Diseases - prevention & control
Arteries - drug effects
Arteries - physiopathology
Arteriosclerosis - drug therapy
Arteriosclerosis - etiology
Arteriosclerosis - prevention & control
Atheroprotective effects
Atherosclerosis
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - drug therapy
Disease Models, Animal
Humans
Hypoglycemic Agents - therapeutic use
Insulin Resistance
Metformin
Metformin - therapeutic use
Obesity - complications
Type 2 diabetes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cardiovascular disease (CVD) is the major determining factor of morbidity and mortality in type 2 diabetic patients. The established relationship between type 2 diabetes and atherosclerosis has fuelled suggestions that anti-diabetic drugs with beneficial effects on CV risk factors may help attenuate the atherosclerotic process in diabetic patients. Metformin is a hypoglycaemic agent widely used in the management of type 2 diabetes. In addition to its insulin-sensitising action, this drug has favourable effects on various CV risk factors and reduces macrovascular complications in obese type 2 diabetic patients. This review summarises in vivo and in vitro experimental evidence on the antiatherogenic properties of metformin.
ISSN:1262-3636
1878-1780
DOI:10.1016/S1262-3636(03)72790-6